Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic).

Hepatotoxic adverse drug reactions are associated with significant morbidity and mortality and are the leading cause of postmarketing regulatory action in the United States. They are classified as Type A (intrinsic) or Type B (idiosyncratic). Type A are predictable, dose-related toxicities, often identified in preclinical or clinical trials, and usually occur in overdose settings or with pre-existing hepatic impairment. Type B are not clearly related to increasing dose and are associated with drug-specific and patient-specific characteristics and environmental risks. Rare Type B reactions are often identified postmarketing. Identification and management, including electronic resources, has evolved.

[1]  Gary S Collins,et al.  Predicting the adverse risk of statin treatment: an independent and external validation of Qstatin risk scores in the UK , 2012, Heart.

[2]  P. Rosenthal,et al.  Intravenous N‐acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo‐controlled clinical trial , 2013, Hepatology.

[3]  P. Watkins,et al.  Liver transplantation for acute liver failure from drug induced liver injury in the United States , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[5]  R. Cabo,et al.  N‐Acetyl cysteine does not prevent liver toxicity from chronic low‐dose plus subacute high‐dose paracetamol exposure in young or old mice , 2016, Fundamental & clinical pharmacology.

[6]  L. Hynan,et al.  Erratum: Intravenous N-Acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure (Gastroenterology (2009) 137 (856-864.e1)) , 2013 .

[7]  R. Andrade,et al.  The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug‐induced liver injury , 2011, Hepatology.

[8]  Yi-Shin Huang.  Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury , 2007, Expert opinion on drug metabolism & toxicology.

[9]  H. Devarbhavi.  An Update on Drug-induced Liver Injury. , 2012, Journal of clinical and experimental hepatology.

[10]  R. Fontana,et al.  Polymerase γ Gene POLG determines the risk of sodium valproate‐induced liver toxicity , 2010, Hepatology.

[11]  G. Gores,et al.  Frequency, clinical presentation, and outcomes of drug‐induced liver injury after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  R. Fontana,et al.  Standardization of nomenclature and causality assessment in drug‐induced liver injury: Summary of a clinical research workshop , 2010, Hepatology.

[13]  Z. Sahnoun,et al.  Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. , 2012, Pathologie-biologie.

[14]  William M. Lee,et al.  Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations , 2013, Hepatology.

[15]  E. Bjornsson,et al.  Hepatotoxicity Associated With Statins: Reports of Idiosyncratic Liver Injury Post-Marketing , 2011 .

[16]  N. Kaplowitz,et al.  Drug-induced liver injury. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  T. Bader.  Yes! Statins can be given to liver patients. , 2012, Journal of hepatology.

[18]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[19]  D. Naisbitt,et al.  Idiosyncratic Adverse Drug Reactions: Current Concepts , 2013, Pharmacological Reviews.

[20]  Chandan Saha,et al.  Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.

[21]  J. Luyendyk,et al.  Ranitidine Treatment during a Modest Inflammatory Response Precipitates Idiosyncrasy-Like Liver Injury in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[22]  William M. Lee,et al.  Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. , 2009, Gastroenterology.

[23]  J. Talwalkar,et al.  Drug‐induced autoimmune hepatitis: Clinical characteristics and prognosis , 2010, Hepatology.

[24]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[25]  H. Bonkovsky,et al.  Drug-Induced Liver Injury with Autoimmune Features , 2014, Seminars in Liver Disease.

[26]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[27]  R. Ulrich,et al.  Idiosyncratic toxicity: a convergence of risk factors. , 2007, Annual review of medicine.

[28]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[29]  A. Czaja.  Drug-Induced Autoimmune-Like Hepatitis , 2011, Digestive Diseases and Sciences.

[30]  William M. Lee.  Toxin- and Drug-Induced Liver Disease , 2012 .

[31]  New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis. , 1998, European cytokine network.

[32]  M. Levy,et al.  Role of Viral Infections in the Induction of Adverse Drug Reactions , 1997, Drug safety.

[33]  C. Stephens,et al.  Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. , 2014, Gastroenterology.

[34]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[35]  H. Conjeevaram,et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.

[36]  J. Marrero,et al.  ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions , 2014, The American Journal of Gastroenterology.

[37]  N. Chalasani,et al.  An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.

[38]  J. Roy,et al.  Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  R. Fontana,et al.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. , 2014, Gastroenterology.

[40]  R. Fontana,et al.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  Dean P. Jones,et al.  Chapter 26 – Drug-Induced Liver Injury , 2006 .

[42]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.